Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period.
Dallas, TX (PRWEB) May 18, 2014
Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 research report says, thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%. Complete report is available at http://www.rnrmarketresearch.com/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-market-report.html.
As per this research, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%. An analyst from the publishing team says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”
These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.
Key marketed products discussed in Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 research report include Herceptin, Halaven, Avastin, Gemzar, Taxotere, Tykerb, Femara, Aromasin, Zoladex and Arimidex. Promising drug candidates in the pipeline discussed in this research include Buparlisib, Palbociclib, Afatinib dimaleate, Entinostat, Neratinib, BMN-673 and Etirinotecan pegol. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=177400.
The analyst continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”
From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options research report. Request a Sample of this report at http://www.rnrmarketresearch.com/contacts/request-sample?rname=177400 for content evaluation before making a purchase decision.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan. The report includes:
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC breast cancer market from 2013 to 2020
- Major marketed products in the APAC region along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends
Another report titled Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies is newly published and of 148 pages. This report says the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020. Complete report is available at http://www.rnrmarketresearch.com/ovarian-cancer-therapeutics-in-major-developed-markets-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market-report.html.
Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=177399.
Explore more reports on the cancer therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics.
RnRMarketResearch.com is an online database of market research reports on 5000+ micro markets. Not limited to the therapeutics industry (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics), RnRMarketResearch.com offers market research studies on all major categories.